| Thymosin alpha in the treatment of chronic hepatitis B: an uncontrolled open-label trial. | |
| | |
MedLine Citation:
|
PMID: 11990327 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Interferon treatment for chronic hepatitis B has low efficacy and is associated with serious side effects. It is therefore important to assess the role of other drugs in the treatment of this condition. AIMS: To assess the efficacy and safety of thymosin alpha in 20 patients with hepatitis B-related liver disease. METHODS: Patients with chronic hepatitis B, HBV DNA positivity, ALT more than 1.5 times the upper limit of normal and liver biopsy showing chronic hepatitis or cirrhosis were treated with thymosin alpha 1.6 mg subcutaneously twice a week for 6 months. Biochemical and serological markers were assessed pre-treatment, immediately post treatment, and 6 months and 1 year after end of treatment. RESULTS: Of 20 patients, 15 had chronic hepatitis and 5 had cirrhosis on histology; 17 were HBeAg-positive and 3 were HBeAg-negative. Eight patients were interferon non-responders and 12 were naïve patients. Four patients had end-of-treatment response and two additional patients had a delayed response within 6 months of treatment; one responder had a relapse within 1 year of treatment. Overall sustained response rate was 25% (5 of 20). No patient cleared HBsAg. Reduction in ALT levels was observed after treatment and persisted one year later. No significant side effects were observed. CONCLUSION: Thymosin alpha is a safe and effective alternative treatment modality in chronic hepatitis B. |
| | |
Authors:
|
Deepak Amarapurkar; Haribhakti Seba Das |
Related Documents
:
|
3168077 - Interferon in chronic active hepatitis b. preliminary results. 12826197 - Nonresponders of interferon/ribavirin treatment for recurrent hepatitis c following liv... 19957327 - Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding... 20154627 - In patients with hcv genotype 2 or 3 infection and rvr 14 weeks treatment is noninferio... 22156887 - Indications and outcomes following complex abdominal reconstruction with component sepa... 10647827 - Combined approach for internal carotid artery stenosis and cardiovascular disease in se... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology Volume: 21 ISSN: 0254-8860 ISO Abbreviation: Indian J Gastroenterol Publication Date: 2002 Mar-Apr |
Date Detail:
|
Created Date: 2002-05-06 Completed Date: 2002-05-23 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8409436 Medline TA: Indian J Gastroenterol Country: India |
Other Details:
|
Languages: eng Pagination: 59-61 Citation Subset: IM |
Affiliation:
|
Bombay Hospital and Research Center, Mumbai. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
therapeutic use* Adult Child Female Follow-Up Studies Hepatitis B, Chronic / drug therapy* Humans Male Prospective Studies Thymosin / analogs & derivatives*, therapeutic use* Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/thymalfasin; 61512-21-8/Thymosin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Response to hepatitis B vaccine in preterm babies.
Next Document: Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis.